Listed

Nuvation Bio Inc.: Form 10-Q for the period ended Jun 30, 2021

Filed with the SEC on Aug 12, 2021 and accepted by EDGAR at Aug 12, 2021, 16:48 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2021-04-01 to 2021-06-30$14.0mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2021-01-01 to 2021-06-30$29.9mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-04-01 to 2021-06-30−$20.4mus-gaap:OperatingIncomeLoss
Operating income6 months2021-01-01 to 2021-06-30−$40.9mus-gaap:OperatingIncomeLoss
Income tax3 months2021-04-01 to 2021-06-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax6 months2021-01-01 to 2021-06-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-04-01 to 2021-06-30−$19.3mus-gaap:NetIncomeLoss
Net income6 months2021-01-01 to 2021-06-30−$39.7mus-gaap:NetIncomeLoss
Operating cash flow6 months2021-01-01 to 2021-06-30−$31.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2021-06-30$449.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-06-30$813.1mus-gaap:AssetsCurrent
Total assetsAt period end2021-06-30$814.3mus-gaap:Assets
Current liabilitiesAt period end2021-06-30$10.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-06-30$25.3mus-gaap:Liabilities
Shareholders' equityAt period end2021-06-30$788.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-21-001385. Last ingested by Listed: Nov 4, 2026, 17:21 ET. Listed shows no prices and gives no investment advice.